January 27, 2025

COLLEGE PARK, Md. & BLOOMINGTON, Minn.--(BUSINESS WIRE)-- IonQ (NYSE: IONQ), the world’s leading quantum company, and SkyWater Technology (NASDAQ: SKYT), the largest exclusively U.S.-based, pure-play semiconductor foundry, today announced they have entered into a definitive agreement pursuant to which IonQ will acquire SkyWater for $35.00 per share in a cash-and-stock transaction, subject to a collar, implying a total equity value of approximately $1.8 billion.

“This transformational acquisition enables IonQ to materially accelerate its quantum computing roadmap and secure its fully scalable supply chain domestically. With secure, U.S.-based design, packaging and chip fabrication – IonQ will benefit from vertical integration across our increasingly interlinked quantum computing, quantum networking, quantum security, and quantum sensing applications for land, sea, air, and space,” said Niccolo de Masi, IonQ Chairman and Chief Executive Officer...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) today announced positive results from its phase 1 study of miroliverELAP®, an external liver assist product, in patients with acute forms of liver failure, acute-on-chronic liver failure, and severe acute alcoholic hepatitis, collectively called acute liver failure (ALF).2

Developed by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP consists of an external blood circuit and a single-use bioengineered liver sustained outside of the human body to provide temporary liver support to ALF patients. The bioengineered liver is manufactured by seeding a decellularized porcine liver scaffold with allogeneic3 human endothelial4 cells and human liver cells isolated from donated human livers. The donated human livers are not suitable for transplantation and are provided by organ procure...

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing Syngene's position as a strategic partner delivering integrated, end-to-end scientific and manufacturing solutions.

Peter Bains, Managing Director and CEO, Syngene International Ltd., said, "Our collaboration with Bristol Myers Squibb, which now spans more than 25...

BALTIMORE--(BUSINESS WIRE)--ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced the publication of a journal article in Pain Physician demonstrating that its HYDRAFIL System for disc augmentation safely generated lasting clinically significant improvements in pain and disability scores in patients with chronic low back pain due to degenerative disc disease. The HYDRAFIL System is an outpatient procedure offering interventional pain physicians and patients a new treatment designed to reduce pain and improve daily function without the need for an invasive surgery.

The article, “Feasibility and Safety of Treatment of Painful Lumbar Degenerative Disc Disease with an Injectable Hydrogel Implant at One Year Follow-up,” evaluated the safety and efficacy of the HYDRAFIL System in... Rating Scale (NRS) for Back Pain by >70% at one year.

Richard Bendis has significant experience building biotech clusters in formerly “flyover” regions (e.g., places that lack the infrastructure to support tech-based entrepreneurs and companies). Around 2009-2010, he was giving a presentation at the National Academy of Sciences in Washington, D.C., on how to build these regions around an industry-driven private-public partnership. After the talk, someone from Johns Hopkins approached him and said they had been trying—with little success—to build a biotech cluster in Maryland. They asked him to come to Montgomery County, Maryland, the epicenter of the region’s life sciences industry.

The NIH Technology Transfer Program was honored with its record 7th “Deal of Distinction Award” at the 2025 Licensing Executives Society Annual Meeting. This award was given to NIH and its licensee Bavarian Nordic for the deal that led to the new chikungunya virus vaccine Vimkunya®. Vimkunya received FDA approval on February 14, 2025, as the first virus-like particle (VLP) single-dose chikungunya vaccine and the first chikungunya vaccine for individuals over the age of 12. It uses virus-like particles designed to mimic the chikungunya virus without the ability to infect cells, replicate or cause disease. This is an important public health development as...

Gaithersburg cancer diagnostics company 20/20 BioLabs Inc. is looking to go public, again — six months after a planned merger that would’ve taken it public fell through.

The company has signaled an intention to list on the Nasdaq Stock Market under ticker symbol “AIDX” through what’s known as a direct listing, 20/20 reported in Securities and Exchange Commission filings.

It’s not a traditional initial public offering in which underwriters offer shares on the public market. In this case, 20/20 BioLabs would list on the exchange and existing stockholders could offer their shares for sale, providing those shareholders with a potential exit while raising the company's profile with a broader pool of investors.

Importantly, 20/20 wouldn’t have any role in setting the prices and, if the sales happen, wouldn’t get any proceeds from them. Up to 15.2 million shares could be offered for sale “at prevailing market prices,” the company said in a prospectus filed with the SEC this week.

by Jonathan Kay, MPP, Managing Partner, Health Market Experts & BioHealth Innovation, Inc. Entrepreneur-in-Residence

Welcome to Tactic 5 in our series of 7 Tactics to Optimize Launch Messaging 🚀 in health and life sciences 🧬. So far in our Optimizing Launch Messaging series, we’ve discussed topics such as the importance of data, the value of tailoring communications to your audience, and the benefit of making communication precise and purposeful. When messaging about a product launch, that included a reminder to focus on benefits and not only on features and functionality. But even the strongest message has limited potential if you can’t quantify its impact. That brings us to Tactic 5, Measuring Success.

Tactic 5: Measure Success

Feedback can be helpful in a variety of contexts. We look for feedback in the market, in a variety of forms of ROI.

In messaging, we look for message recall, impact, attribution.

We also want to know which...

BioHealth Innovation is expanding its Entrepreneurs in Residence (EIR) network and is seeking experienced leaders at the intersection of biohealth and advanced technologies, including artificial intelligence and quantum computing.

This call is for seasoned operators with a strong commercialization background. Ideal candidates have taken innovations from concept through market entry, licensing, spinout, or acquisition, and understand the realities of regulatory pathways, customer discovery, fundraising, and scale. Experience working with startups, academic technologies, government labs, or early-stage venture-backed companies is essential. EIRs serve in a part time advisory role with BHI, working flexibly alongside other professional commitments while contributing hands on commercialization expertise.

Email BHI Founder, President, CEO Rich Bendis if you are interested.

By Sara Gilgore – Staff Reporter, Washington Business Journal - The owner of GSK PLC’s soon-to-be-vacant Rockville R&D campus is gearing up for a significant renovation to reposition the site’s three buildings for a range of tenants — and not just biopharma companies.

San Francisco-based GI Partners plans to overhaul the 635,000-square-foot complex at 14200 Shady Grove Road after British pharmaceutical giant vacates when its lease runs out in June.

The work would modernize the space and create common areas for tenants to interact, said Matt Brady, president of Rockville’s Scheer Partners, which is marketing the property.

As to what types of tenants fill it? The buildings were created for scientific research, but could also serve other types of users — from government agencies to university research arms to quantum computing companies.

“It could take on a lot of different paths, even simultaneously,” Brady said.

January 17, 2026 - Higher Medicine Inc. today announced a strategic investment and fundraising partnership with Cerdwen, a venture capital firm focused on health and performance technology innovation.

Based in West Chester, Pennsylvania, Cerdwen partners with visionary founders to advance transformative healthcare technologies, supporting the translation of bold scientific ideas into meaningful clinical and commercial impact.

“Higher Medicine exemplifies the type of company we seek to partner with: rigorous science, a focused initial indication, and a platform capable of expanding into significant unmet medical needs,” said Kevin Brophy, Managing Principal of Cerdwen. “Dr. Kim and his team are tackling complex CNS disorders with a differentiated epigenetic approach, and we believe the company is well-positioned to translate that ambition into clinical impact.”

“Higher Medicine was founded on a simple but ambitious belief: that many devastating brain disorders need not be lifelong sentences,” said Dr. Leo Kim, Founder and CEO of Higher Medicine. “By harnessing epigenetic biology, we aim to prevent, slow, or even reverse conditions that few companies are willing to confront. Our initial focus on Kabuki syndrome is a deliberate...”

GAITHERSBURG, Md., Jan. 20, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under the terms of the agreement, Pfizer will obtain a non-exclusive license for Matrix-M for use with Pfizer's products in up to two disease areas.

"The Novavax team is excited about this agreement with Pfizer to access our Matrix-M® technology in its future development plans," said John C. Jacobs, President and Chief Executive Officer, Novavax. "This agreement, along with other recently formed partnerships, is further evidence of the potential utility of Matrix-M for the development of new products."

Under the terms of the license agreement:

Novavax will receive an upfront payment of $30 million and the potential to receive up to $500 million in development and sales milestones.

In addition to milestone payments, Novavax is eligible to receive tiered high mid-single digit percentage royalty payments on sales of any product by Pfizer that includes Matrix-M.

Pfizer will be solely responsible for the development and commercialization of its products utilizing Matrix-M.



Novavax will be responsible for the supply of Matrix-M.